HER2-positive cancer

Representative image of a cancer care specialist reviewing gastroesophageal scan data as BeOne Medicines’ HER2-positive gastroesophageal cancer results draw attention after ASCO 2026.

Pharma & Biotech

Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?

by Pallavi Madhiraju
May 28, 2026
0 Comments

Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.

Read More

Representative image: Ensoma’s EN-374 clinical safety data highlight the growing promise of in vivo hematopoietic stem cell engineering for X-linked chronic granulomatous disease, as gene therapy developers test whether one-time treatments can move beyond complex ex vivo manufacturing and into scalable clinical use.

Pharma & Biotech

Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering

by Pallavi Madhiraju
May 10, 2026
0 Comments

In vivo gene therapy has reached human HSC engineering. Ensoma’s EN-374 safety data raise a bigger question: can durability follow?

Read More